MOLN
Molecular Partners AG American Depositary Shares
Biological Products, (No Diagnostic Substances)
Best Biotech Stocks 2026 →
Molecular Partners (MOLN) Stock: Buy, Sell, or Hold?
$3.01
-0.08 (-2.59%)
▼
5d:
-2.59%
30d:
-21.82%
90d:
-22.82%
QUANTITATIVE VERDICT
WAIT
LOW Confidence (84%)
Quality Score
47/100
Position
OVERSOLD
30-Day Fair Range
$3.29 – $3.82
Position: OVERSOLD
Forward P/E & Valuation
-29.2x
CHEAP
vs 31.9x historical avg
Wall Street Target
$10.11
+227.3% upside
Options IV & Volume
HIGH Vol
HIGH volume confirmation
Support / Resistance
$3.00 / $3.80
Trend: Downtrend
Executive Thesis & Bottom Line
Forward Earnings Fair Value & Price Prediction →
📊 MIXED SIGNALS: MOLN shows conflicting indicators. Wait for confirmation before entering.
Get Alerted When MOLN Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
In-depth Analysis How we analyze
Valuation Analysis: MOLN is currently trading at $3.01, which is considered oversold relative to its 30-day fair value range of $3.29 to $3.82. From a valuation perspective, the stock is trading at a discount (Forward PE: -29.1) compared to its historical average (31.9). At these levels, the market is pricing in 0% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, MOLN is in a downtrend. The price is currently testing key support at $3.00. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock scores a mixed 43/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $10.11 (+227.3%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, MOLN is in a downtrend. The price is currently testing key support at $3.00. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock scores a mixed 43/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $10.11 (+227.3%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$3.29 -
$3.82
Company Quality Score
47/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
84.3%
Trading Range & Key Levels
30-Day Trading Range
$3.29 -
$3.82
Current vs Trading Range
OVERSOLD
Support Level
$3.00
Resistance Level
$3.80
Current Trend
Downtrend
Technical data as of
Nov 12, 2026
Quantitative Signal Breakdown
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (43/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 227.3% below Wall St target ($10.11)
- BULLISH: Market expects only 0% annual growth - appears undervalued
- WARNING: Composite score 47/100 in the bottom quintile — this cohort historically lags the market
Fundamental Context
Forward P/E (Next Year Est.)
-29.15
Wall Street Target
$10.11
(+227.3%)
Revenue Growth (YoY)
-100.0%
PE vs Historical
-29.2 vs 31.9
CHEAP
Share MOLN Analysis
Share this live MOLN analysis (with rich preview card) to Reddit, StockTwits, X, or embed the chart on your blog.
bloggers & journalists: you are free to use our charts with attribution.
Last updated: November 12, 2026 2:45 PM ET
Data refreshes hourly during market hours. Next update: 3:45 PM
Data refreshes hourly during market hours. Next update: 3:45 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is MOLN showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
RVMD
Revolution Medicines Inc |
STRONG BUY
25 analysts |
$261 | 38 SELL |
|
IONS
Ionis Pharmaceuticals Inc |
STRONG BUY
25 analysts |
$84 | 45 HOLD |
|
ACLX
Arcellx Inc |
STRONG BUY
18 analysts |
$113 | 50 HOLD |
|
VKTX
Viking Therapeutics Inc |
STRONG BUY
21 analysts |
$95 | 41 HOLD |
|
ABVX
Abivax SA American Depos… |
STRONG BUY
12 analysts |
$164 | 64 BUY |
Explore More Analysis & Live Quant Tools
Part A: Deep-Dive MOLN Research Pages
